BR9807627A - Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos. - Google Patents

Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos.

Info

Publication number
BR9807627A
BR9807627A BR9807627-2A BR9807627A BR9807627A BR 9807627 A BR9807627 A BR 9807627A BR 9807627 A BR9807627 A BR 9807627A BR 9807627 A BR9807627 A BR 9807627A
Authority
BR
Brazil
Prior art keywords
factor
analogue
preparation containing
preparation
preparing
Prior art date
Application number
BR9807627-2A
Other languages
English (en)
Inventor
Michele Himmelspach
Uwe Schlokat
Friedrich Dorner
Andreas Fischer
Johann Eibl
Original Assignee
Baxter Aktiengesellchaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Aktiengesellchaft filed Critical Baxter Aktiengesellchaft
Publication of BR9807627A publication Critical patent/BR9807627A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ANáLOGO DE FATOR X, DNA RECOMBINANTE CODIFICANTE PARA UM ANáLOGO DE FATOR X, PREPARAçãO CONTENDO UM ANáLOGO DE FATOR X PURIFICADO OU UMA SUA PROTEìNA PRECURSORA, PREPARAçãO CONTENDO ANáLOGO DE FATOR XA APRESENTANDO ALTA ESTABILIDDE E INTEGRIDADE ESTRUTURAL, USOS DE UMA PREPARAçãO E DE UM áCIDO NUCLEICO, E, PROCESSOS PARA A PREPARAçãO DE UM PREPARADO CONTENDO ANáLOGO DE FATOR X RECOMBINANTE PURIFICADO, E PARA SE PREPARAR UM PREPARADO CONTENDO FATOR XA OU ANáLOGO DE FATOR XA ATIVOS". A invenção refere-se a análogos de Fator X que têm uma modificação na área do sítio de clivagem de ativação de Fator Xa naturalmente ocorrente, sendo que a referida modificação representa um sítio de processamento de uma protease que não cliva naturalmente nesta área da seq³ência do Fator X. A invenção também refere-se a preparações contendo os inéditos análogos de Fator X e a processos para sua produção.
BR9807627-2A 1997-02-27 1998-02-27 Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos. BR9807627A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0033597A AT405516B (de) 1997-02-27 1997-02-27 Faktor x-analoge mit modifizierter proteasespaltstelle
PCT/AT1998/000045 WO1998038317A1 (de) 1997-02-27 1998-02-27 Faktor x-analoge mit modifizierter proteasespaltstelle

Publications (1)

Publication Number Publication Date
BR9807627A true BR9807627A (pt) 2000-02-22

Family

ID=3487868

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807627-2A BR9807627A (pt) 1997-02-27 1998-02-27 Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos.

Country Status (17)

Country Link
US (2) US6573071B1 (pt)
EP (1) EP0966536B1 (pt)
JP (1) JP4317976B2 (pt)
AR (1) AR012034A1 (pt)
AT (2) AT405516B (pt)
AU (1) AU744428B2 (pt)
BR (1) BR9807627A (pt)
CA (1) CA2282707A1 (pt)
CZ (1) CZ298298B6 (pt)
DE (1) DE59813518D1 (pt)
ES (1) ES2263199T3 (pt)
HU (1) HU225246B1 (pt)
IL (2) IL131346A0 (pt)
NO (1) NO327878B1 (pt)
PL (1) PL190734B1 (pt)
SK (1) SK286359B6 (pt)
WO (1) WO1998038317A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405517B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
IL129427A0 (en) * 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
US20040102388A1 (en) * 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
US7223577B2 (en) * 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
US20040132156A1 (en) * 2002-10-04 2004-07-08 Schering Aktiengesellschaft Modified hepsin molecules having a substitute activation sequence and uses thereof
US8828939B2 (en) * 2004-08-17 2014-09-09 Csl Behring Gmbh Modified vitamin K dependent polypeptides
EP1728798A1 (en) * 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP2014676B1 (en) 2006-04-20 2012-03-07 Kringle Pharma Inc. Hgf precursor protein mutant and activated form thereof
US9956272B2 (en) 2007-05-30 2018-05-01 Bio Products Laboratory Limited Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
GB0710321D0 (en) * 2007-05-30 2007-07-11 Nhs Blood & Transplant Method
KR20100058541A (ko) * 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
ES2597436T3 (es) 2007-09-28 2017-01-18 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
EP2364165B1 (en) * 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
EP3121271B1 (en) * 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
PT2440228T (pt) * 2009-06-08 2018-12-24 Amunix Operating Inc Polipéptidos de regulação da glicose e métodos de preparação e utilização dos mesmos
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2453910B1 (en) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
CA2864904C (en) 2012-02-15 2023-04-25 Amunix Operating Inc. Factor viii compositions and methods of making and using same
EP3549953A1 (en) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
CN107496932A (zh) 2012-02-27 2017-12-22 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
GB201211617D0 (en) * 2012-06-29 2012-08-15 Univ Aberdeen Production of cyclic peptides
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
CN105008530A (zh) * 2013-03-12 2015-10-28 诺和诺德股份有限公司 凝血酶敏感性凝固因子x分子
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
RU2585532C2 (ru) * 2014-01-31 2016-05-27 Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук"(ФИЦ Биотехнологии РАН) Плазмида для экспрессии рекомбинантного фактора свёртываемости крови ix человека, клетка сно - продуцент рекомбинантного фактора свёртываемости крови ix человека и способ получения указанного фактора
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
IL307276A (en) 2015-08-28 2023-11-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
KR102613936B1 (ko) * 2020-11-13 2023-12-15 한국생명공학연구원 자가분해능이 저하된 켁신 효소 및 이의 생산 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT366916B (de) * 1980-04-02 1982-05-25 Immuno Ag Vorrichtung zur applikation eines gewebeklebstoffes auf basis von menschlichen oder tierischenproteinen
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
AT382783B (de) * 1985-06-20 1987-04-10 Immuno Ag Vorrichtung zur applikation eines gewebeklebstoffes
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
JP4236698B2 (ja) 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
DE4325872C1 (de) 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
AT404838B (de) 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
AT405517B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon

Also Published As

Publication number Publication date
ES2263199T3 (es) 2006-12-01
AT405516B (de) 1999-09-27
CZ303299A3 (cs) 2000-02-16
IL131346A (en) 2007-05-15
AR012034A1 (es) 2000-09-27
HUP0100652A3 (en) 2003-01-28
PL335382A1 (en) 2000-04-25
HU225246B1 (en) 2006-08-28
SK286359B6 (sk) 2008-08-05
US7220569B2 (en) 2007-05-22
WO1998038317A1 (de) 1998-09-03
NO994139L (no) 1999-10-27
AU6200298A (en) 1998-09-18
CZ298298B6 (cs) 2007-08-22
SK117199A3 (en) 2000-05-16
IL131346A0 (en) 2001-01-28
NO327878B1 (no) 2009-10-12
DE59813518D1 (de) 2006-06-01
CA2282707A1 (en) 1998-09-03
NO994139D0 (no) 1999-08-26
ATA33597A (de) 1999-01-15
US20030181381A1 (en) 2003-09-25
HUP0100652A1 (hu) 2001-06-28
JP4317976B2 (ja) 2009-08-19
EP0966536A1 (de) 1999-12-29
ATE324454T1 (de) 2006-05-15
JP2001513631A (ja) 2001-09-04
PL190734B1 (pl) 2005-12-30
US6573071B1 (en) 2003-06-03
EP0966536B1 (de) 2006-04-26
AU744428B2 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
BR9807627A (pt) Análogo de fator x, dna recombinante codificante para um análogo de fator x, preparação contendo um análogo de fator x purificado ou uma sua proteìna precursora, preparação contendo análogo de fator xa apresentando alta estabilidade e integridade estrutural, usos de uma preparação e de um ácido nucleico, e, processos para a preparação de um preparado contendo análogo de fator x recombinante purificado, e para se preparar um preparado contendo fator xa ou análogo de fator xa ativos.
Nutt et al. The amino acid sequence of antistasin. A potent inhibitor of factor Xa reveals a repeated internal structure.
RU95115239A (ru) Аналог эритропоэтина
HUP9902698A2 (hu) Humán bikunin
AR004668A1 (es) Un acido nucleico aislado purificado, un vector de expresion recombinante que lo comprende, una celula que comprende dicho vector, un metodo para laproduccion de un polipeptido de h.pylori, una composicion de vacuna, el uso de dicha composicion para preparar medicamentos, un polipeptido purificado de h.
BR9807618A (pt) Análogo de fator xdelta, dna recombinante codificante para um análogo de fator xdelta, células transformadas, preparação, uso da mesma, e, processos para produzir uma preparação contendo análogo de fator xdelta recombinante purificado e análogo de fator xa.
Grant et al. Biosynthesis of an insulin precursor by islet tissue of cod (Gadus callarias)
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
PT91099A (pt) Processo de preparacao de peptidos de ligacao a proteases de retroviros, dos seus intermediarios e de composicoes farmaceuticas
AU4880093A (en) Retrovirus from the HIV group and its use
DK471085D0 (da) Farmaceutiske sammensaetninger indeholdende syntetiske phospholipiderog et farmaceutisk aktivt stof samt deres fremstilling og anvendelse
PT81168B (pt) Processo para a preparacao de proteinas inibidoras da coagulacao do sangue e de composicoes farmaceuticas contendo estas substancias
HUP9800075A2 (hu) Nukleinsav-konstrukciók proteázokkal aktíválható hatóanyagok expresszálására valamint előállításuk és alkalmazásuk
ES2028796T3 (es) Procedimiento para producir preparados farmaceuticos que contienen interferon alfa.
ATE84048T1 (de) Peptid, dessen verfahren zur herstellung, sie enthaltende pharmazeutische zusammensetzung und benutzung.
PT81991B (pt) Processo para a preparacao de derivados peptidicos, analogos a pepestatina, inibidores darenina e das proteases acidas
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
BR9710615A (pt) Uso de um agente na manufatura de um medicamento para o tratamento de doença metabólica óssea, e, agente de anti-absorção óssea.
US5397694A (en) Protease inhibitor
Tam et al. The importance of disulfide bridges in human endopeptidase (enkephalinase) after proteolytic cleavage
EP0210279A4 (en) STABILIZED HUMAN PROUROKINASE.
PT81345B (pt) Processo para a preparacao de novos peptideos activos sobre o sistema nervoso central com accao sobre o sistema colinergico, e de composicoes farmaceuticas contendo estes compostos
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
PT704527E (pt) Sequencias de adn que codificam precursores de insulina biossinteticos e processo para a preparacao de insulina
IT1222427B (it) Procedimento per la purificazione di interferone

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A, 6A,7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1887 DE 06/03/2007.